Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bright Green Co. stock logo
BGXX
Bright Green
$0.05
$0.03
$0.54
$11.47M-0.26360,154 shs25,935 shs
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
$0.25
-2.8%
$0.28
$0.22
$3.42
$11.33M0.481.15 million shs689,420 shs
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
$0.22
-4.6%
$0.23
$0.14
$0.63
$14.08M1.76.46 million shs792,988 shs
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
$0.97
-7.2%
$1.04
$0.82
$9.00
$3.15M1.842.09 million shs109,736 shs
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bright Green Co. stock logo
BGXX
Bright Green
0.00%0.00%0.00%+50.00%-70.54%
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-2.81%-1.29%-17.07%-14.50%-91.70%
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
-4.63%-12.09%-16.24%-16.37%-18.28%
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
-7.24%-6.35%-12.25%-43.04%+9.44%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bright Green Co. stock logo
BGXX
Bright Green
N/AN/AN/AN/AN/AN/AN/AN/A
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
2.2151 of 5 stars
3.25.00.00.02.40.00.6
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
2.2481 of 5 stars
0.05.00.04.63.31.70.0
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
2.9354 of 5 stars
3.55.00.00.02.21.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bright Green Co. stock logo
BGXX
Bright Green
0.00
N/AN/AN/A
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
2.33
Hold$12.504,985.44% Upside
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
2.33
HoldN/AN/A
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
3.00
Buy$3.00208.01% Upside

Current Analyst Ratings Breakdown

Latest VRAX, BGXX, CLRB, and GLYC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
3/31/2025
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$3.00
3/21/2025
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bright Green Co. stock logo
BGXX
Bright Green
N/AN/AN/AN/A$0.06 per shareN/A
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/AN/AN/AN/A($0.96) per shareN/A
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
$10K1,408.09N/AN/A$0.08 per share2.73
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
$84.87K37.10N/AN/A$2.00 per share0.49
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bright Green Co. stock logo
BGXX
Bright Green
-$13.13M-$0.06N/AN/AN/AN/A-88.37%-55.30%N/A
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-$42.77M-$0.73N/AN/AN/AN/AN/A-191.22%8/11/2025 (Estimated)
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
-$37.88M-$0.46N/AN/AN/AN/A-230.74%-177.39%8/14/2025 (Estimated)
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
-$6.73MN/A0.00N/AN/AN/AN/AN/A

Latest VRAX, BGXX, CLRB, and GLYC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
-$0.05-$0.04+$0.01-$0.04N/AN/A
5/13/2025Q1 2025
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-$0.17-$0.13+$0.04-$0.14N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bright Green Co. stock logo
BGXX
Bright Green
N/AN/AN/AN/AN/A
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/AN/AN/AN/AN/A
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
N/AN/AN/AN/AN/A
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bright Green Co. stock logo
BGXX
Bright Green
N/A
0.01
0.01
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/A
1.77
1.77
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
N/A
1.92
1.92
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
N/A
11.57
11.39

Institutional Ownership

CompanyInstitutional Ownership
Bright Green Co. stock logo
BGXX
Bright Green
7.83%
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
16.41%
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
75.19%
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
8.61%

Insider Ownership

CompanyInsider Ownership
Bright Green Co. stock logo
BGXX
Bright Green
62.55%
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
3.70%
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
8.70%
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
45.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bright Green Co. stock logo
BGXX
Bright Green
2191.17 million71.59 millionNo Data
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
1046.08 million44.38 millionOptionable
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
5064.53 million58.90 millionOptionable
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
53.23 million1.78 millionNot Optionable

Recent News About These Companies

Virax Biolabs Announces Strategic Goals and Developments for 2025
Virax Biolabs Sees Asset Growth Amid Financial Loss
Virax Biolabs announces distribution agreement with Europa Biosite
Virax Biolabs Expands Reach with Europa Biosite Deal

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bright Green stock logo

Bright Green NASDAQ:BGXX

Bright Green Corporation focuses on the cultivation, manufacture, and sale of cannabis and cannabis-related products. Its products are used in research, pharmaceutical applications, and affiliated exports. The company was incorporated in 2019 and is based in Grants, New Mexico.

Cellectar Biosciences stock logo

Cellectar Biosciences NASDAQ:CLRB

$0.25 -0.01 (-2.81%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$0.24 0.00 (-1.95%)
As of 05/28/2025 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

GlycoMimetics stock logo

GlycoMimetics NASDAQ:GLYC

$0.22 -0.01 (-4.63%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$0.22 0.00 (-0.09%)
As of 05/28/2025 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Virax Biolabs Group stock logo

Virax Biolabs Group NASDAQ:VRAX

$0.97 -0.08 (-7.24%)
Closing price 05/28/2025 03:59 PM Eastern
Extended Trading
$0.98 +0.00 (+0.31%)
As of 05/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.